Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Vilazodone | hsa00030 | Pentose phosphate pathway | 6.58E-04 | 4 | P60891, P51854, P52209, P37837 | PRPS1, TKTL1, PGD, TALDO1 | More | | Vilazodone | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Vilazodone | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Vilazodone | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Vilazodone | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Vilazodone | hsa00220 | Arginine biosynthesis | 6.63E-05 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Vilazodone | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | | Vilazodone | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Vilazodone | hsa00500 | Starch and sucrose metabolism | 1.91E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Vilazodone | hsa00510 | N-Glycan biosynthesis | 3.15E-02 | 2 | P15907, Q9NR34 | ST6GAL1, MAN1C1 | More | | Vilazodone | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | Vilazodone | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | | Vilazodone | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Vilazodone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Vilazodone | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Vilazodone | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | | Vilazodone | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | Vilazodone | hsa00670 | One carbon pool by folate | 1.33E-02 | 2 | P04818, Q99707 | TYMS, MTR | More | | Vilazodone | hsa00730 | Thiamine metabolism | 1.55E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Vilazodone | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | Vilazodone | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Vilazodone | hsa00830 | Retinol metabolism | 2.27E-03 | 5 | P00325, P11766, P00352, Q9BPW9, O75911 | ADH1B, ADH5, ALDH1A1, DHRS9, DHRS3 | More | | Vilazodone | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Vilazodone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Vilazodone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Vilazodone | hsa00983 | Drug metabolism - other enzymes | 1.50E-03 | 5 | P04183, P20839, P32320, P05164, Q16772 | TK1, IMPDH1, CDA, MPO, GSTA3 | More | | Vilazodone | hsa01040 | Biosynthesis of unsaturated fatty acids | 4.28E-02 | 1 | P22307 | SCP2 | More | | Vilazodone | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Vilazodone | hsa01230 | Biosynthesis of amino acids | 2.98E-03 | 5 | P51854, P60891, P05089, P15104, P37837 | TKTL1, PRPS1, ARG1, GLUL, TALDO1 | More | | Vilazodone | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Vilazodone | hsa01523 | Antifolate resistance | 1.88E-03 | 4 | P41440, Q92820, P04818, P01375 | SLC19A1, GGH, TYMS, TNF | More | | Vilazodone | hsa01524 | Platinum drug resistance | 4.94E-02 | 2 | P78417, P52701 | GSTO1, MSH6 | More | | Vilazodone | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Vilazodone | hsa03010 | Ribosome | 7.34E-03 | 6 | P62753, P62829, P62888, P61927, P61513, P36578 | RPS6, RPL23, RPL30, RPL37, RPL37A, RPL4 | More | | Vilazodone | hsa03020 | RNA polymerase | 2.14E-04 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | Vilazodone | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Vilazodone | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Vilazodone | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Vilazodone | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Vilazodone | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | | Vilazodone | hsa04012 | ErbB signaling pathway | 1.91E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Vilazodone | hsa04015 | Rap1 signaling pathway | 2.13E-03 | 6 | P06213, P25116, Q8TEU7, O00522, P08514, P17252 | INSR, F2R, RAPGEF6, KRIT1, ITGA2B, PRKCA | More | | Vilazodone | hsa04020 | Calcium signaling pathway | 8.77E-03 | 3 | P21796, P30679, P23634 | VDAC1, GNA15, ATP2B4 | More | | Vilazodone | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | Vilazodone | hsa04060 | Cytokine-cytokine receptor interaction | 1.41E-03 | 13 | P14784, P27930, P14778, P26842, Q06643, Q13651, P78552, P25024, Q9UBD3, P47992, O75509, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, IL13RA1, CXCR1, XCL2, XCL1, TNFRSF21, CXCL1, CD4 | More | | Vilazodone | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | | Vilazodone | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | | Vilazodone | hsa04064 | NF-kappa B signaling pathway | 4.99E-09 | 19 | P10415, O00463, P14778, P01584, P01375, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P63279, P24522, Q8NHW4, P09341, Q06643, Q9NQC7 | BCL2, TRAF5, IL1R1, IL1B, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, UBE2I, GADD45A, CCL4L2, CXCL1, LTB, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.744 | Q04759 | PRKCQ | Protein kinase C theta type | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.81 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.932 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.945 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.721 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.83 | Q04759 | PRKCQ | Protein kinase C theta type | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.76 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.877 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q8WV28 | BLNK | B-cell linker protein | -0.704 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13315 | ATM | Serine-protein kinase ATM | 0.752 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.756 | Q04759 | PRKCQ | Protein kinase C theta type | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.846 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.75 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | Q04759 | PRKCQ | Protein kinase C theta type | P09341 | CXCL1 | Growth-regulated alpha protein | -0.885 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09341 | CXCL1 | Growth-regulated alpha protein | -0.802 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.799 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.825 |
| Vilazodone | hsa04070 | Phosphatidylinositol signaling system | 1.62E-03 | 5 | P19174, P49619, Q86XP1, P27987, Q96DU7 | PLCG1, DGKG, DGKH, ITPKB, ITPKC | More | | Vilazodone | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | | Vilazodone | hsa04110 | Cell cycle | 9.48E-06 | 9 | Q9UBD5, P06493, O60566, Q14683, P30304, P33981, P42773, P01106, Q13547 | ORC3, CDK1, BUB1B, SMC1A, CDC25A, TTK, CDKN2C, MYC, HDAC1 | More | | Vilazodone | hsa04120 | Ubiquitin mediated proteolysis | 1.08E-03 | 6 | Q9UBT2, Q14145, Q13042, P62837, Q15751, Q14669 | SAE2, KEAP1, CDC16, UBE2D2, HERC1, TRIP12 | More | | Vilazodone | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Vilazodone | hsa04142 | Lysosome | 1.46E-05 | 11 | Q99437, P25774, P06865, P22304, P38571, Q13510, Q9UJJ9, P07602, Q9NRA2, P49279, P61916 | ATP6V0B, CTSS, HEXA, IDS, LIPA, ASAH1, GNPTG, PSAP, SLC17A5, SLC11A1, NPC2 | More | | Vilazodone | hsa04144 | Endocytosis | 2.00E-04 | 9 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q8WU79, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, SMAP1L, GIT2, SNX12 | More | | Vilazodone | hsa04145 | Phagosome | 2.59E-02 | 9 | O75015, Q15080, Q99437, P05164, P78380, O60603, P35443, P13765, P25774 | FCGR3B, NCF4, ATP6V0B, MPO, OLR1, TLR2, THBS4, HLA-DOB, CTSS | More | | Vilazodone | hsa04151 | PI3K-Akt signaling pathway | 7.39E-03 | 7 | P62753, O43521, P27348, Q8WYR1, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, PIK3R5, ATF4, SGK, PIK3AP1 | More | | Vilazodone | hsa04210 | Apoptosis | 3.63E-02 | 3 | O75460, O43521, P18848 | ERN1, BCL2L11, ATF4 | More | | Vilazodone | hsa04213 | Longevity regulating pathway - multiple species | 3.98E-03 | 3 | Q08828, P51828, P0DMV8 | ADCY1, ADCY7, HSPA1A | More | | Vilazodone | hsa04217 | Necroptosis | 2.37E-06 | 11 | P01375, P48023, Q9NQC7, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q9H444 | TNF, FASLG, CYLD, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CHMP4B | More | | Vilazodone | hsa04260 | Cardiac muscle contraction | 4.02E-02 | 2 | P09493, P14927 | TPM1, UQCRB | More | | Vilazodone | hsa04270 | Vascular smooth muscle contraction | 2.36E-04 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | Vilazodone | hsa04310 | Wnt signaling pathway | 5.60E-03 | 3 | P30279, Q13485, O43318 | CCND2, SMAD4, MAP3K7 | More | | Vilazodone | hsa04380 | Osteoclast differentiation | 9.58E-05 | 13 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, Q8N149, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, LILRA2, SIRPA | More | | Vilazodone | hsa04512 | ECM-receptor interaction | 2.93E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Vilazodone | hsa04520 | Adherens junction | 3.91E-02 | 2 | Q13485, O43318 | SMAD4, MAP3K7 | More | | Vilazodone | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Vilazodone | hsa04610 | Complement and coagulation cascades | 6.10E-07 | 3 | P09871, P0C0L4, P20023 | C1S, C4A, CR2 | More | | Vilazodone | hsa04611 | Platelet activation | 9.37E-05 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | | Vilazodone | hsa04612 | Antigen processing and presentation | 1.86E-04 | 8 | P13765, P48382, P01730, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, CD4, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Vilazodone | hsa04613 | Neutrophil extracellular trap formation | 1.21E-05 | 26 | P19174, P16109, P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, P0C0S5, Q99878, Q93077, P62807, Q16778, O60814, P68431, Q15080, P08311, O75015, P21730, P08514, P21462, P07359, O43315, Q16539 | PLCG1, SELP, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AFZ, H2AC14, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, CTSG, FCGR3B, C5AR1, ITGA2B, FPR1, GP1BA, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.785 | Q15746 | MYLK | Myosin light chain kinase, smooth muscle | P16109 | SELP | P-selectin | 0.776 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P11215 | ITGAM | Integrin alpha-M | 0.795 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05164 | MPO | Myeloperoxidase | 0.719 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08246 | ELA2 | Neutrophil elastase | 0.702 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.813 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.731 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q92769 | HDAC2 | Histone deacetylase 2 | -0.7 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P04908 | H2AC4; H2AC8 | Histone H2A type 1-B/E | 0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P0C0S5 | H2AFZ | Histone H2A.Z | 0.785 | Q15746 | MYLK | Myosin light chain kinase, smooth muscle | Q99878 | H2AC14 | Histone H2A type 1-J | 0.76 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.737 | P11712 | CYP2C9 | Cytochrome P450 2C9 | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.754 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.702 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.702 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | Q16778 | HIST2H2BE | Histone H2B type 2-E | 0.728 | P11712 | CYP2C9 | Cytochrome P450 2C9 | O60814 | H2BC12 | Histone H2B type 1-K | 0.728 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.913 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.845 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.762 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08311 | CTSG | Cathepsin G | 0.744 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.983 | Q15746 | MYLK | Myosin light chain kinase, smooth muscle | P08514 | ITGA2B | Integrin alpha-IIb | 0.812 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.839 | Q15746 | MYLK | Myosin light chain kinase, smooth muscle | P07359 | GP1BA | Platelet glycoprotein Ib alpha chain | 0.814 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | O43315 | AQP9 | Aquaporin-9 | -0.764 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O43315 | AQP9 | Aquaporin-9 | 0.934 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | -0.744 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 |
| Vilazodone | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Vilazodone | hsa04621 | NOD-like receptor signaling pathway | 2.12E-03 | 10 | P01584, P07900, Q14643, P10599, P43490, O00463, P29728, P01375, P09341, P12838 | IL1B, HSP90AA1, ITPR1, TXN, PBEF1, TRAF5, OAS2, TNF, CXCL1, DEFA4 | More | | Vilazodone | hsa04623 | Cytosolic DNA-sensing pathway | 1.65E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | | Vilazodone | hsa04625 | C-type lectin receptor signaling pathway | 9.91E-04 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Vilazodone | hsa04630 | JAK-STAT signaling pathway | 3.20E-02 | 4 | P01106, P42224, P14784, Q13651 | MYC, STAT1, IL2RB, IL10RA | More | | Vilazodone | hsa04640 | Hematopoietic cell lineage | 1.02E-07 | 18 | P13612, P07359, P08514, P14778, P27930, P15144, P20023, P11836, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375, P01584 | ITGA4, GP1BA, ITGA2B, IL1R1, IL1R2, ANPEP, CR2, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF, IL1B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13612 | ITGA4 | Integrin alpha-4 | -0.797 | P06239 | LCK | Tyrosine-protein kinase Lck | P13612 | ITGA4 | Integrin alpha-4 | 0.732 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13612 | ITGA4 | Integrin alpha-4 | 0.774 | Q15746 | MYLK | Myosin light chain kinase, smooth muscle | P07359 | GP1BA | Platelet glycoprotein Ib alpha chain | 0.814 | Q15746 | MYLK | Myosin light chain kinase, smooth muscle | P08514 | ITGA2B | Integrin alpha-IIb | 0.812 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q04759 | PRKCQ | Protein kinase C theta type | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.733 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.926 | P06239 | LCK | Tyrosine-protein kinase Lck | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.727 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P15144 | ANPEP | Aminopeptidase N | 0.851 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P15144 | ANPEP | Aminopeptidase N | -0.757 | Q15746 | MYLK | Myosin light chain kinase, smooth muscle | P20023 | CR2 | Complement receptor type 2 | 0.727 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P11836 | MS4A1 | B-lymphocyte antigen CD20 | -0.71 | Q04759 | PRKCQ | Protein kinase C theta type | P25063 | CD24 | Signal transducer CD24 | -0.903 | P06239 | LCK | Tyrosine-protein kinase Lck | P25063 | CD24 | Signal transducer CD24 | -0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P25063 | CD24 | Signal transducer CD24 | -0.839 | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | Q04759 | PRKCQ | Protein kinase C theta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.861 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.781 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.803 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06493 | CDK1 | Cyclin-dependent kinase 1 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.732 | P06493 | CDK1 | Cyclin-dependent kinase 1 | P06127 | CD5 | T-cell surface glycoprotein CD5 | -0.739 | P06239 | LCK | Tyrosine-protein kinase Lck | P09564 | CD7 | T-cell antigen CD7 | 0.84 | P06493 | CDK1 | Cyclin-dependent kinase 1 | P09564 | CD7 | T-cell antigen CD7 | -0.735 | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 |
| Vilazodone | hsa04650 | Natural killer cell mediated cytotoxicity | 6.01E-07 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O14931, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.761 | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | Q04759 | PRKCQ | Protein kinase C theta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.855 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.823 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.862 | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | Q04759 | PRKCQ | Protein kinase C theta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.849 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.82 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.852 | Q04759 | PRKCQ | Protein kinase C theta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.918 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.91 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.922 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.778 | Q04759 | PRKCQ | Protein kinase C theta type | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.803 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.846 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.943 | Q04759 | PRKCQ | Protein kinase C theta type | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.803 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.846 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.943 |
| Vilazodone | hsa04657 | IL-17 signaling pathway | 1.10E-05 | 9 | P07900, O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Vilazodone | hsa04658 | Th1 and Th2 cell differentiation | 6.50E-15 | 16 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, P42224, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT1, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.827 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.723 | Q04759 | PRKCQ | Protein kinase C theta type | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.904 | Q04759 | PRKCQ | Protein kinase C theta type | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.867 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | Q04759 | PRKCQ | Protein kinase C theta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.843 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.713 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
| Vilazodone | hsa04659 | Th17 cell differentiation | 2.15E-11 | 17 | Q04759, Q16539, P19174, P01730, P06239, P42224, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, P01584, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, IL1B, CD3E, CD3G, CD247, JAK1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.827 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.723 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q04759 | PRKCQ | Protein kinase C theta type | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.8 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.713 | Q04759 | PRKCQ | Protein kinase C theta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.843 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | Q04759 | PRKCQ | Protein kinase C theta type | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.867 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 |
| Vilazodone | hsa04660 | T cell receptor signaling pathway | 2.91E-09 | 14 | P01375, Q9UDY8, Q04759, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.721 | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | Q04759 | PRKCQ | Protein kinase C theta type | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.733 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.925 | Q04759 | PRKCQ | Protein kinase C theta type | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.803 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.866 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 1 | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | Q04759 | PRKCQ | Protein kinase C theta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.861 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.781 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.803 | Q04759 | PRKCQ | Protein kinase C theta type | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.767 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.803 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.811 | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.812 |
| Vilazodone | hsa04662 | B cell receptor signaling pathway | 4.53E-03 | 3 | P20023, Q8WV28, P11912 | CR2, BLNK, CD79A | More | | Vilazodone | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | | Vilazodone | hsa04668 | TNF signaling pathway | 1.56E-03 | 8 | P01375, O00463, Q16539, P18848, P01584, P20749, P14780, P20333 | TNF, TRAF5, MAPK14, ATF4, IL1B, BCL3, MMP9, TNFRSF1B | More | | Vilazodone | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | | Vilazodone | hsa04710 | Circadian rhythm | 4.40E-02 | 1 | O15516 | CLOCK | More | | Vilazodone | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Vilazodone | hsa04722 | Neurotrophin signaling pathway | 1.98E-03 | 5 | Q05655, P49841, O43524, P48023, P52566 | PRKCD, GSK3B, FOXO3, FASLG, ARHGDIB | More | | Vilazodone | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | | Vilazodone | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Vilazodone | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Vilazodone | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.32E-03 | 10 | P14778, P01584, Q08828, P51828, P22694, Q16539, Q14643, Q04759, P0DP24, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2, CALM1 | More | | Vilazodone | hsa04912 | GnRH signaling pathway | 5.53E-03 | 8 | Q08828, P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P0DP23, P22694 | ADCY1, ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, CALM1, PRKACB | More | | Vilazodone | hsa04913 | Ovarian steroidogenesis | 2.52E-02 | 1 | P06213 | INSR | More | | Vilazodone | hsa04915 | Estrogen signaling pathway | 4.64E-04 | 5 | Q08828, P51828, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, NCOA1 | More | | Vilazodone | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | Vilazodone | hsa04919 | Thyroid hormone signaling pathway | 1.64E-02 | 4 | P19174, P42224, Q13547, P01106 | PLCG1, STAT1, HDAC1, MYC | More | | Vilazodone | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | | Vilazodone | hsa04924 | Renin secretion | 4.69E-02 | 2 | P07550, P0DP23 | ADRB2, CALM1 | More | | Vilazodone | hsa04926 | Relaxin signaling pathway | 4.94E-02 | 2 | P63218, P30679 | GNG5, GNA15 | More | | Vilazodone | hsa04930 | Type II diabetes mellitus | 1.48E-03 | 2 | P06213, Q05655 | INSR, PRKCD | More | | Vilazodone | hsa04932 | Non-alcoholic fatty liver disease | 8.68E-08 | 13 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, P12074, O15239, Q16718, O95298, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA1, NDUFA5, NDUFC2, SDHD | More | | Vilazodone | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Vilazodone | hsa04960 | Aldosterone-regulated sodium reabsorption | 8.56E-04 | 3 | O00141, P06213, P48048 | SGK, INSR, KCNJ1 | More | | Vilazodone | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Vilazodone | hsa04966 | Collecting duct acid secretion | 1.38E-03 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | Vilazodone | hsa04970 | Salivary secretion | 2.14E-03 | 4 | P07550, Q08828, P51828, P0DP23 | ADRB2, ADCY1, ADCY7, CALM1 | More | | Vilazodone | hsa04976 | Bile secretion | 3.14E-03 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | Vilazodone | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | | Vilazodone | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Vilazodone | hsa05016 | Huntington disease | 3.74E-03 | 10 | O95298, P13073, P12074, P24928, P30876, P62487, P05141, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4, PSMD12 | More | | Vilazodone | hsa05017 | Spinocerebellar ataxia | 2.16E-02 | 2 | Q8TB72, P21796 | PUM2, VDAC1 | More | | Vilazodone | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Vilazodone | hsa05022 | Pathways of neurodegeneration - multiple diseases | 6.94E-04 | 13 | P49841, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, P01584, Q08752, P0DP24 | GSK3B, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, IL1B, PPID, CALM2 | More | | Vilazodone | hsa05034 | Alcoholism | 5.45E-04 | 6 | Q13547, Q93077, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Vilazodone | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | Vilazodone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | Vilazodone | hsa05131 | Shigellosis | 2.57E-02 | 2 | Q05655, P07737 | PRKCD, PFN1 | More | | Vilazodone | hsa05132 | Salmonella infection | 4.88E-02 | 2 | P84095, P07737 | RHOG, PFN1 | More | | Vilazodone | hsa05133 | Pertussis | 4.24E-03 | 1 | P0C0L4 | C4A | More | | Vilazodone | hsa05134 | Legionellosis | 2.82E-02 | 3 | P01584, Q9NR31, P0DMV8 | IL1B, SAR1A, HSPA1A | More | | Vilazodone | hsa05140 | Leishmaniasis | 2.22E-04 | 10 | P13612, O75015, P23458, P13765, O60603, P01375, P01584, P49006, Q16539, Q15080 | ITGA4, FCGR3B, JAK1, HLA-DOB, TLR2, TNF, IL1B, MARCKSL1, MAPK14, NCF4 | More | | Vilazodone | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Vilazodone | hsa05144 | Malaria | 1.43E-04 | 8 | P60033, P69905, P68871, O60603, P01375, P35443, P01584, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Vilazodone | hsa05146 | Amoebiasis | 3.53E-07 | 10 | P01584, P09341, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | IL1B, CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | Q04759 | PRKCQ | Protein kinase C theta type | P09341 | CXCL1 | Growth-regulated alpha protein | -0.885 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09341 | CXCL1 | Growth-regulated alpha protein | -0.802 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q04759 | PRKCQ | Protein kinase C theta type | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.733 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.926 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.811 | P06239 | LCK | Tyrosine-protein kinase Lck | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.727 | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O60603 | TLR2 | Toll-like receptor 2 | 0.73 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O60603 | TLR2 | Toll-like receptor 2 | -0.714 | Q04759 | PRKCQ | Protein kinase C theta type | P05089 | ARG1 | Arginase-1 | -0.899 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05089 | ARG1 | Arginase-1 | 0.848 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05089 | ARG1 | Arginase-1 | 0.702 | P06239 | LCK | Tyrosine-protein kinase Lck | P05089 | ARG1 | Arginase-1 | -0.803 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P05089 | ARG1 | Arginase-1 | -0.868 | Q04759 | PRKCQ | Protein kinase C theta type | P22694 | PRKACB | cAMP-dependent protein kinase catalytic subunit beta | 0.755 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P22694 | PRKACB | cAMP-dependent protein kinase catalytic subunit beta | -0.772 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P22694 | PRKACB | cAMP-dependent protein kinase catalytic subunit beta | 0.873 | Q04759 | PRKCQ | Protein kinase C theta type | P12814 | ACTN1 | Alpha-actinin-1 | -0.821 | P06239 | LCK | Tyrosine-protein kinase Lck | P12814 | ACTN1 | Alpha-actinin-1 | -0.867 | Q04759 | PRKCQ | Protein kinase C theta type | P08311 | CTSG | Cathepsin G | -0.913 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08311 | CTSG | Cathepsin G | 0.744 | P06239 | LCK | Tyrosine-protein kinase Lck | P08311 | CTSG | Cathepsin G | -0.816 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P08311 | CTSG | Cathepsin G | -0.866 |
| Vilazodone | hsa05150 | Staphylococcus aureus infection | 4.83E-02 | 2 | P09871, P16109 | C1S, SELP | More | | Vilazodone | hsa05152 | Tuberculosis | 4.16E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | | Vilazodone | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Vilazodone | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | Vilazodone | hsa05163 | Human cytomegalovirus infection | 2.84E-04 | 15 | P01375, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, P04637, O00463 | TNF, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, TP53, TRAF5 | More | | Vilazodone | hsa05169 | Epstein-Barr virus infection | 7.68E-05 | 13 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P42224, P01375, P29728, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, STAT1, TNF, OAS2, CD3E, CD3G, CD247 | More | | Vilazodone | hsa05171 | Coronavirus disease - COVID-19 | 3.18E-03 | 7 | P01584, P62753, P36578, P62888, P61927, P61513, P62829 | IL1B, RPS6, RPL4, RPL30, RPL37, RPL37A, RPL23 | More | | Vilazodone | hsa05200 | Pathways in cancer | 1.44E-02 | 5 | Q13485, P52701, P30279, P63218, P78417 | SMAD4, MSH6, CCND2, GNG5, GSTO1 | More | | Vilazodone | hsa05202 | Transcriptional misregulation in cancer | 7.50E-05 | 17 | Q13315, P17844, P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | ATM, DDX5, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13315 | ATM | Serine-protein kinase ATM | 0.752 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P17844 | DDX5 | Probable ATP-dependent RNA helicase DDX5 | 0.863 | Q04759 | PRKCQ | Protein kinase C theta type | P14780 | MMP9 | Matrix metalloproteinase-9 | -0.787 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.94 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P14780 | MMP9 | Matrix metalloproteinase-9 | -0.855 | Q04759 | PRKCQ | Protein kinase C theta type | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.733 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.926 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.727 | Q04759 | PRKCQ | Protein kinase C theta type | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | -0.745 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | -0.833 | Q04759 | PRKCQ | Protein kinase C theta type | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.76 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.877 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.83 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P35226 | BMI1 | Polycomb complex protein BMI-1 | 0.76 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P35226 | BMI1 | Polycomb complex protein BMI-1 | 0.76 | Q04759 | PRKCQ | Protein kinase C theta type | P05164 | MPO | Myeloperoxidase | -0.88 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05164 | MPO | Myeloperoxidase | 0.719 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P05164 | MPO | Myeloperoxidase | -0.811 | Q04759 | PRKCQ | Protein kinase C theta type | P12838 | DEFA4 | Neutrophil defensin 4 | -0.833 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P12838 | DEFA4 | Neutrophil defensin 4 | 0.784 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P12838 | DEFA4 | Neutrophil defensin 4 | -0.86 | Q04759 | PRKCQ | Protein kinase C theta type | P08246 | ELA2 | Neutrophil elastase | -0.748 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08246 | ELA2 | Neutrophil elastase | 0.702 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P08246 | ELA2 | Neutrophil elastase | -0.782 | Q04759 | PRKCQ | Protein kinase C theta type | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | 0.774 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.783 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | 0.9 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.919 | Q04759 | PRKCQ | Protein kinase C theta type | Q13547 | HDAC1 | Histone deacetylase 1 | 0.723 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q92769 | HDAC2 | Histone deacetylase 2 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P12980 | LYL1 | Protein lyl-1 | 0.784 | Q04759 | PRKCQ | Protein kinase C theta type | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.846 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.75 |
| Vilazodone | hsa05203 | Viral carcinogenesis | 1.29E-03 | 7 | Q13547, Q15283, P12814, P06493, P62807, Q16778, O60814 | HDAC1, RASA2, ACTN1, CDK1, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Vilazodone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Vilazodone | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | | Vilazodone | hsa05210 | Colorectal cancer | 4.94E-02 | 2 | Q13485, P52701 | SMAD4, MSH6 | More | | Vilazodone | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Vilazodone | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | Vilazodone | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Vilazodone | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Vilazodone | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | | Vilazodone | hsa05231 | Choline metabolism in cancer | 2.57E-05 | 7 | Q02750, P09619, Q9GZP0, O15245, Q9Y259, P19174, P49619 | MAP2K1, PDGFRB, PDGFD, SLC22A1, CHKB, PLCG1, DGKG | More | | Vilazodone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.85E-07 | 13 | O95267, P19174, P07766, P20963, P09693, P06239, P23458, P42224, O60603, Q04759, Q16539, Q9HC35, P01730 | RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, JAK1, STAT1, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q04759 | PRKCQ | Protein kinase C theta type | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.733 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.785 | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.744 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.827 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.723 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O60603 | TLR2 | Toll-like receptor 2 | 0.73 | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P51955 | NEK2 | Serine/threonine-protein kinase Nek2 | Q9HC35 | EML4 | Echinoderm microtubule-associated protein-like 4 | 0.716 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.707 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 |
| Vilazodone | hsa05310 | Asthma | 1.25E-05 | 4 | P13765, P29965, P12724, P01375 | HLA-DOB, CD40LG, RNASE3, TNF | More | | Vilazodone | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Vilazodone | hsa05321 | Inflammatory bowel disease | 2.41E-08 | 8 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B, IL21R | More | | Vilazodone | hsa05322 | Systemic lupus erythematosus | 2.21E-05 | 7 | P09871, Q93077, P62807, Q16778, O60814, P68431, P12814 | C1S, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1 | More | | Vilazodone | hsa05330 | Allograft rejection | 1.76E-03 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | | Vilazodone | hsa05332 | Graft-versus-host disease | 5.22E-06 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Vilazodone | hsa05340 | Primary immunodeficiency | 2.22E-03 | 6 | P01730, P01732, P11912, Q8WV28, P07766, P06239 | CD4, CD8A, CD79A, BLNK, CD3E, LCK | More | | Vilazodone | hsa05410 | Hypertrophic cardiomyopathy | 1.73E-02 | 2 | P26012, P09493 | ITGB8, TPM1 | More | | Vilazodone | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.08E-05 | 8 | Q8IZS8, P54284, P14923, P15924, P08514, P13612, P26012, Q9UJU2 | CACNA2D3, CACNB3, JUP, DSP, ITGA2B, ITGA4, ITGB8, LEF1 | More | | Vilazodone | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | Vilazodone | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Vilazodone | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | | Vilazodone | hsa05418 | Fluid shear stress and atherosclerosis | 1.26E-04 | 8 | Q16539, Q14145, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | | |